Morphine for dysnea in patients with lung fibrosis

Palliation of dyspnea with morphine in patients with interstitial lung disease - MORPHILD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2015-002533-22-DK

Enrollment

Registered

2015-06-12

Start date

2015-08-31

Completion date

Unknown

Last updated

2020-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung disease

Interventions

Product Name: Morphine hydrochloride Pharmaceutical Form: Oral drops INN or Proposed INN: Røde dråber CAS Number: 52-26-6 Current Sponsor code: Røde dråber Other descriptive name: MORPHINE HYDROCHLORI

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • A diagnosis of interstitial lung disease (IPF, NSIP, RA-ILS, Scl-ILS, MCTD-ILS, asbestosis, drug induced ILD, un classified ILD) • Dyspnea Medial Research Councils (MRC) dyspnea score = 3 • Informed written consent • Age = 18 years • Habile • For fertile women: negative HCG before inclusion • For fertile and sexualle active persons: Secure birth control during the study period and the day after Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range 18 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 18

Exclusion criteria

Exclusion criteria: • Treatment with morpine or morphne analogues • Allergy towards morphine

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate if morphine hydrochloride administered for 7 days is safe and attenuates dyspnea in patients with interstitial lung disease and dyspnea;Secondary Objective: To investigate if the abovementioned treatment reduces anxiety and improvesexercise capacity;Primary end point(s): Change in VAS dyspnea score after 7 days treatment with oral morhine drops;Timepoint(s) of evaluation of this end point: at baseline and after 7 days	—

Measure

Time frame

Main Objective: To investigate if morphine hydrochloride administered for 7 days is safe and attenuates dyspnea in patients with interstitial lung disease and dyspnea;Secondary Objective: To investigate if the abovementioned treatment reduces anxiety and improvesexercise capacity;Primary end point(s): Change in VAS dyspnea score after 7 days treatment with oral morhine drops;Timepoint(s) of evaluation of this end point: at baseline and after 7 days

—

Secondary

Measure	Time frame
Secondary end point(s): Frequency of breathing Blood pressure and pulse Arterial oxygen and CO2 content 6 min walk test distance, peripheral saturation and Borgs dyspnea score at the 6 min walk test Cough (VAS and Leicester cough score) ILD specific life quality (KBILD) depression and anxiety score (GAD-7). ;Timepoint(s) of evaluation of this end point: At baseline and after 7 days	—

Countries

Denmark

Contacts

Public ContactDept of respiratory diseases

Aarhus University Hospital

karbends@rm.dk

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026